Targeting the lung using siRNA and antisense based oligonucleotides

Sterghios A Moschos1, Karen Spinks, Andrew E Williams

  • 1Respiratory Research Group, Wythenshawe Hospital, School of Translational Medicine, University of Manchester, M23 9LT, UK.

Insights

The lung is a promising target for oligonucleotide therapeutics via inhalation. This review explores challenges in antisense and siRNA delivery, stability, and immune responses for effective lung-targeted treatments.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Respiratory Medicine

Background:

  • The lung's large surface area and accessibility via inhalation make it an attractive site for topical drug delivery.
  • Oligonucleotide-based therapeutics, including antisense and small interfering RNA (siRNA), show potential for treating lung diseases.

Purpose of the Study:

  • To critically review the challenges and opportunities for using antisense and siRNA therapeutics targeting the lung.
  • To evaluate key factors influencing the efficacy and safety of inhaled oligonucleotide therapies.

Main Methods:

  • Literature review focusing on in vivo target validation for antisense and siRNA approaches.
  • Analysis of factors including delivery, distribution, stability, off-target effects, and immunogenicity.
  • Discussion on the selection of optimal messenger RNA (mRNA) targets for therapeutic intervention.

Main Results:

  • Inhalation offers a viable route for topical lung delivery of oligonucleotide therapeutics.
  • Significant challenges remain in achieving effective delivery, distribution, and stability within lung tissues.
  • Off-target effects and unwanted immune responses are critical safety considerations for these therapies.

Conclusions:

  • Despite challenges, the lung presents a significant therapeutic target for oligonucleotide-based drugs.
  • Further research is needed to optimize delivery systems and overcome biological barriers for successful clinical application.
  • Careful target selection and mitigation of adverse effects are crucial for developing safe and effective lung oligonucleotide therapies.

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...